18F LY3546117
Alternative Names: 18F-LY3546117Latest Information Update: 03 Feb 2021
At a glance
- Originator Avid Radiopharmaceuticals
- Class Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 Feb 2021 Preclinical trials in Solid tumours (Diagnosis) in USA (IV) prior to February 2021
- 02 Feb 2021 Avid radiopharmaceuticals plans a phase I trial in Solid tumours(Diagnosis) in Australia (IV, Injection) in April 2021 (NCT04721756)